Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Earnings for Paratek Pharmaceuticals, Inc. (PRTK)
Earnings in 2022 (TTM): $-63,509,000
According to Paratek Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-63,509,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Paratek Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-63,509,000 | $-63,566,000 |
| 2021 | $-58,484,000 | $-59,084,000 |
| 2020 | $-96,541,000 | $-116,259,000 |
| 2019 | $-128,489,000 | $-128,790,000 |
| 2018 | $-111,854,000 | $-112,356,000 |
| 2017 | $-88,316,000 | $-89,069,000 |
| 2016 | $-111,636,000 | $-111,636,000 |
| 2015 | $-70,860,000 | $-70,860,000 |
| 2014 | $-17,835,000 | $-17,835,000 |
| 2013 | $-27,446,000 | $-27,446,000 |
| 2012 | $-12,016,000 | $-12,016,000 |
| 2011 | $-3,950,000 | $-3,880,000 |
| 2010 | $-9,418,000 | $-9,303,000 |
| 2009 | $-24,127,000 | $-21,800,000 |
| 2008 | $34.82 M | $34.82 M |
| 2007 | $-32,531,000 | $-32,531,000 |
| 2006 | $-29,628,000 | $-29,628,000 |
| 2005 | $ | $-23,805,000 |
| 2004 | $ | $-17,952,000 |
| 2003 | $ | $-12,775,000 |
| 2002 | $ | $-5,636,000 |
| 2001 | $ | $-1,581,000 |